BioCentury
ARTICLE | Company News

Caris, Lustgarten deal

January 27, 2017 9:13 PM UTC

Caris and the foundation partnered to conduct a Phase II trial of melanoma drug Keytruda pembrolizumab in patients with microsatellite unstable tumors. Caris is responsible for trial enrollment, and L...

BCIQ Company Profiles

Caris Life Sciences Inc.